Finance Watch: BridgeBio’s Oncology Spinout Reveals Go-Public Plan

 
• By Mandy Jackson

Public Company Edition: BridgeBio Oncology Therapeutics will merger with a SPAC and raise $450m. Also, BridgeBio Pharma priced $500m in notes and Solid grossed $200m in a follow-on offering, while Idorsia restructured debt and a deal after a planned transaction fizzled out.

Finance Watch Public Company
• Source: Alamy

More from Finance Watch

More from Scrip